Fig. 2: Diagrammatic illustration of the mode of action of conventional and novel therapies used to manage TP53-mutated acute myeloid leukemia.
From: What have we learned about TP53-mutated acute myeloid leukemia?
(ADC, antibody-drug conjugate; mAb; monoclonal antibody, DART; dual affinity retargeting antibody, MHC; major histocompatibility complex).
